Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA

Launched by CHINESE UNIVERSITY OF HONG KONG · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new diagnostic test that aims to improve the detection of pleural tuberculosis (TB), a type of TB that affects the lining around the lungs. The current methods for diagnosing this condition are often not accurate enough, which can lead to unnecessary procedures and delays in treatment. The new test looks for specific DNA from the TB bacteria in the pleural fluid, which could help doctors make a more confident diagnosis. Additionally, it may also help identify if the TB strain is resistant to certain treatments.

To participate in the trial, individuals must be 18 years or older and have a new build-up of fluid around their lungs that requires a procedure called thoracentesis. However, those who have had previous TB in the same area or have undergone certain surgeries or treatments in the past will not be eligible. Participants can expect to provide pleural fluid samples for testing, which could lead to a quicker and less invasive diagnosis, ultimately improving their care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • New-onset pleural effusion planning for thoracentesis
• • Age 18 years or above
• • Able to give informed consent
• Exclusion Criteria:
• • History of TBP or intrapleural therapy (including talc and fibrinolytic) in the ipsilateral pleural space. Patients with a history of TB outside the pleural space completed anti-TB treatment can be included
• • History of surgical intervention (including decortication, pleurodesis, lung resection) in the ipsilateral pleural space
• • Concomitant use of at least two anti-TB medications (including isoniazid, rifampicin, pyrazinamide, ethambutol, amikacin, streptomycin, levofloxacin, moxifloxacin, linezolid) for more than consecutive 7 days in the past 3 months
• • Consent not obtained from the participants